Literature DB >> 20073040

Reporting cumulative proportion of subjects with an adverse event based on data from multiple studies.

Christy Chuang-Stein1, Mohan Beltangady.   

Abstract

Experience has shown us that when data are pooled from multiple studies to create an integrated summary, an analysis based on naïvely-pooled data is vulnerable to the mischief of Simpson's Paradox. Using the proportions of patients with a target adverse event (AE) as an example, we demonstrate the Paradox's effect on both the comparison and the estimation of the proportions. While meta analytic approaches have been recommended and increasingly used for comparing safety data between treatments, reporting proportions of subjects experiencing a target AE based on data from multiple studies has received little attention. In this paper, we suggest two possible approaches to report these cumulative proportions. In addition, we urge that regulatory guidelines on reporting such proportions be established so that risks can be communicated in a scientifically defensible and balanced manner.
Copyright © 2010 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2011        PMID: 20073040     DOI: 10.1002/pst.397

Source DB:  PubMed          Journal:  Pharm Stat        ISSN: 1539-1604            Impact factor:   1.894


  7 in total

Review 1.  Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab.

Authors:  D Arnold; C S Fuchs; J Tabernero; A Ohtsu; A X Zhu; E B Garon; J R Mackey; L Paz-Ares; A D Baron; T Okusaka; T Yoshino; H H Yoon; M Das; D Ferry; Y Zhang; Y Lin; P Binder; A Sashegyi; I Chau
Journal:  Ann Oncol       Date:  2017-12-01       Impact factor: 32.976

2.  Pooling Different Safety Data Sources: Impact of Combining Solicited and Spontaneous Reports on Signal Detection In Pharmacovigilance.

Authors:  Jeremy D Jokinen; Rosalind J Walley; Michael W Colopy; Thomas S Hilzinger; Peter Verdru
Journal:  Drug Saf       Date:  2019-10       Impact factor: 5.606

3.  Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss.

Authors:  Sean Wharton; Salvatore Calanna; Melanie Davies; Dror Dicker; Bryan Goldman; Ildiko Lingvay; Ofri Mosenzon; Domenica M Rubino; Mette Thomsen; Thomas A Wadden; Sue D Pedersen
Journal:  Diabetes Obes Metab       Date:  2021-10-04       Impact factor: 6.408

Review 4.  Thoratec CentriMag for temporary treatment of refractory cardiogenic shock or severe cardiopulmonary insufficiency: a systematic literature review and meta-analysis of observational studies.

Authors:  Oleg Borisenko; Gillian Wylie; John Payne; Staffan Bjessmo; Jon Smith; Nizar Yonan; Richard Firmin
Journal:  ASAIO J       Date:  2014 Sep-Oct       Impact factor: 2.872

5.  The FDA's Final Rule on Expedited Safety Reporting: Statistical Considerations.

Authors:  Janet Wittes; Brenda Crowe; Christy Chuang-Stein; Achim Guettner; David Hall; Qi Jiang; Daniel Odenheimer; H Amy Xia; Judith Kramer
Journal:  Stat Biopharm Res       Date:  2015-10-09       Impact factor: 1.452

6.  On estimands and the analysis of adverse events in the presence of varying follow-up times within the benefit assessment of therapies.

Authors:  Steffen Unkel; Marjan Amiri; Norbert Benda; Jan Beyersmann; Dietrich Knoerzer; Katrin Kupas; Frank Langer; Friedhelm Leverkus; Anja Loos; Claudia Ose; Tanja Proctor; Claudia Schmoor; Carsten Schwenke; Guido Skipka; Kristina Unnebrink; Florian Voss; Tim Friede
Journal:  Pharm Stat       Date:  2018-11-20       Impact factor: 1.894

7.  Data monitoring committees for clinical trials evaluating treatments of COVID-19.

Authors:  Tobias Mütze; Tim Friede
Journal:  Contemp Clin Trials       Date:  2020-09-19       Impact factor: 2.226

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.